Bertold Emmerich

4.7k citations

114 papers · 3.5k indexed · h-index 32

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments

Papers in

Genetics 44
- Chronic Lymphocytic Leukemia Research 41
Hematology 31
- Multiple Myeloma Research and Treatments 12
- Acute Myeloid Leukemia Research 9
- Chronic Myeloid Leukemia Treatments 8

Co-authors: Michael Hallek Ralf Schmidmaier Philipp Baumann Gerold Meinhardt Wolfgang Hiddemann Raymonde Busch Alex Smith P.J. Wyld
Journals: Blood (14 papers)British Journal of Haematology (10 papers)Annals of Hematology (8 papers)Journal of Molecular Medicine (5 papers)Leukemia (3 papers)
Partner nations: Germany United States Austria

In The Last Decade

Bertold Emmerich

108 papers receiving 3.4k citations

Peers

Countries citing papers authored by Bertold Emmerich

Since Specialization

Citations

This map shows the geographic impact of Bertold Emmerich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertold Emmerich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertold Emmerich more than expected).

Fields of papers citing papers by Bertold Emmerich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertold Emmerich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertold Emmerich. The network helps show where Bertold Emmerich may publish in the future.

Co-authors

The 25 scholars most cited alongside Bertold Emmerich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bertold Emmerich Line = papers co-authored together Bertold Emmerich links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood ·Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Martina Stauch, Manuela A. Bergmann, Matthias Ritgen, N Kranzhöfer, Robert Rohrberg, Ulrike Söling, Oswald Burkhard, Anne Westermann, Valentin Goede, Carmen D. Schweighofer, Kirsten Fischer, Anna‐Maria Fink, Clemens‐Martin Wendtner, Günter Brittinger, Hartmut Döhner, Bertold Emmerich, Michael Hallek, (unknown)	2009	238
2	Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis Cancer ·Stefan Früehauf, Julian Topaly, Eike C. Buss, Thomas Fischer, Oliver G. Ottmann, Bertold Emmerich, Martin C. Müller, Peter Schuld, Leopold Balleisen, Rüdiger Hehlmann, Anthony D. Ho, Andreas Hochhaus	2007	43
3	A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells Leukemia ·Colin Jamieson, Julia Stieglmaier, Christian Kellner, Matthias Peipp, Domenica Saul, Fuat Oduncu, Bertold Emmerich, Bernhard Stockmeyer, Peter Lang, Jörn D. Beck, G H Fey	2007	23
4	Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1 Experimental Hematology ·Ralf Schmidmaier, Mark F. Oellerich, Joachim Baumgart, Bertold Emmerich, Gerold Meinhardt	2004	28
5	Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) Leukemia ·C.‐M. Wendtner, Matthias Ritgen, Florence Watt, Guenter Fingerle-Rowson, Hartmut Campe, Gundula Jäger, Barbara Eichhorst, Robert Busch, Heinz Diem, Andreas Engert, Stephan Stilgenbauer, Hartmut Döhner, Michael Kneba, Bertold Emmerich, Michael Hallek, (unknown)	2004	201
6	Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group Blood ·Barbara Eichhorst, Raymonde Busch, Martina Stauch, Michael Kneba, Matthias Ritgen, Sinan Alnashi, Oswald Burkhard, Michael Bergmann, Clemens‐Martin Wendtner, Wolfgang Hiddemann, Bertold Emmerich, Michael Hallek, Yue Deng	2003	9
7	Fludarabine, Mitoxantrone and Cyclophosphamide Combination Therapy in Relapsed Chronic Lymphocytic Leukemia with or without G-CSF Results of the First Interim Ananlysis of a Phase III Study of the German CLL Study Group Blood ·Barbara Schmitt, Astrid Franke, Oswald Burkhard, Rudolf Schlag, Georg Hopfinger, Martina Stauch, Michael Bergmann, Clemens‐Martin Wendtner, Raymonde Busch, Bertold Emmerich, Michael Hallek, Yue Deng	2002	3
8	Lymphadenopathy detected by ultrasound examination as first diagnostic hint of chronic lymphocytic leukaemia in a patient with melanoma Journal of the European Academy of Dermatology and Venereology ·M.-H. Schmid-Wendtner, Annette Lebeau, 张东红, Matthias Volkenandt, Bertold Emmerich, Christina F. Pelajo [missing]	2002	7
9	Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy Annals of Oncology ·C.‐M. Wendtner, Barbara Schmitt, Mathias Wilhelm, Peter Dreger, Emili Montserrat, Bertold Emmerich, Michael Hallek	1999	11
10	Signaling Defect in the Activation of Caspase-3 and PKCδ in Human TUR Leukemia Cells Is Associated with Resistance to Apoptosis Experimental Cell Research ·Gerold Meinhardt, 小田光希, Karine ABIVEN, Godelieve van Heteren, Bertold Emmerich, Ralf Hass	1999	29
11	Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. PubMed ·Michael Hallek, Carola A. Neumann, Moshe Schaffer, S. Danhauser-Riedl, Nikolas von Bubnoff, Gabriele de Vos, Brian Druker, Kiyoshi Yasukawa, James D. Griffin, Bertold Emmerich	1997	63
12	Interleukin‐6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP‐1 European Journal of Immunology ·Carola A. Neumann, Doni Nofra, S. Danhauser-Riedl, Bertold Emmerich, Michael Hallek	1996	24
13	Interaction of the receptor tyrosine kinase p145^c‐kit with the p210^bcr/abl kinase in myeloid cells British Journal of Haematology ·Michael Hallek, S. Danhauser-Riedl, Ronald Herbst, Markus Warmuth, 施峰, 山西哲郎, Brian Druker, J D Griffin, Bertold Emmerich, A. Ullrich	1996	40
14	Interferon‐alpha 2b (IFNα) for Early‐Phase Chronic Lymphocytic Leukaemia with High Risk for Disease Progression: Results of a Randomized Multicentre Study British Journal of Haematology ·Irmgard Langenmayer, Christoph Nerl, Wolfgang Knauf, محمد محمد بسيوني قنديل, Michael Hallek, 大西一正, Hermann Dietzfelbinger, Raymonde Busch, H.W.L. Ziegler-Heitbrock, Eckhard Thiel, Bertold Emmerich	1996	15
15	Building a cytology report database: a computer-assisted system for documentation, evaluation and hospital-wide recall of haematological biopsy reports Medical Informatics ·Б Б Серков, August König, Martin R. Fischer, Bernd Hertenstein, Bertold Emmerich	1994	1
16	lnterferon-alpha2b for Early Phase Chronic Lymphocytic Leukemia with High Risk for Progression – First Results of a Randomized Multicenter AlO-Study Oncology Research and Treatment ·Wolfgang Knauf, Sapriani Gustina, C. Nerl, Hermann Dietzfelbinger, P. Maubach, H.W.L. Ziegler-Heitbrock, Bertold Emmerich, E. Thiel	1992	1
17	Proteolytic Inactivation of alpha₁-Proteinase Inhibitor in vivo: Detection, Characterization and Quantitation of the Main Fragment Excreted in the Urine of Leukemia Patients Biological Chemistry Hoppe-Seyler ·Robert Dengler, Jakob Steiger, F. Lottspeich, Andreas Plewan, Adaling Ogilvie, Bertold Emmerich	1992	4
18	Highly fluorochrome labeled gene probes for quantitative tracing of RNA in individual cells by in situ hybridization Bioconjugate Chemistry ·Katharina Pachmann, М. В. Рябухина, Bertold Emmerich, Salomó MARQUÉS	1991	7
19	In situ amplification of single copy gene segments in individual cells by the polymerase chain reaction Infection ·W Spann, Katharina Pachmann, H. R. Muralidhar, Elizabeth McNeill, Bertold Emmerich	1991	27
20	Changes in Clonal Growth, Immunophenotype, and Morphology During a Follow-up Study of an Acute Lymphoblastic Leukemia Hämatologie und Bluttransfusion ·Albrecht Reichle, Martin Volkmann, Katharina Pachmann, H. Diddens, Bertold Emmerich, Johann Rastetter	1990	1

About Bertold Emmerich

Bertold Emmerich is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Oncology, having authored 114 papers that have together received 3.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (28 papers), Multiple Myeloma Research and Treatments (12 papers), Immunodeficiency and Autoimmune Disorders (12 papers), Acute Lymphoblastic Leukemia research (11 papers), Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Immune Cell Function and Interaction (7 papers). The work is most often cited by research in Genetics (1.7k citations), Hematology (916 citations), Pathology and Forensic Medicine (1.3k citations), Immunology (1.2k citations) and Oncology (759 citations). Bertold Emmerich has collaborated with scholars based in Germany, United States and Austria. Frequent co-authors include Michael Hallek, Ralf Schmidmaier, Philipp Baumann, Gerold Meinhardt, Wolfgang Hiddemann, Raymonde Busch, Alex Smith, P.J. Wyld, S.A. Johnson and H. Löffler. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Hematology, Journal of Molecular Medicine and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact